or Try an Advanced Search...

    Technical Analysis for JANX - Janux Therapeutics, Inc.

    Grade Last Price % Change Price Change
    C 48.29 -1.37% -0.67
    JANX closed down 0.1 percent on Wednesday, November 20, 2024, on 59 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    3 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Down Down
    Historical JANX trend table...
    Date Alert Name Type % Chg
    NR7 Range Contraction -1.37%
    Lower Bollinger Band Walk Weakness -1.37%
    Inside Day Range Contraction -1.37%
    Lower Bollinger Band Touch Weakness -1.37%
    Oversold Stochastic Weakness -1.37%
    MACD Bearish Centerline Cross Bearish -1.47%
    Bullish Engulfing Bullish -1.47%
    Lower Bollinger Band Walk Weakness -1.47%
    BB Squeeze Ended Range Expansion -1.47%
    Lower Bollinger Band Touch Weakness -1.47%
    Older End-of-Day Signals for JANX ...

       Recent Intraday Alerts

    Alert Time
    Down 2 % 21 minutes ago
    Lower Bollinger Band Support 21 minutes ago
    Rose Above Previous Day's High 29 minutes ago
    Down 1% 29 minutes ago
    Up 1% 29 minutes ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    JANX Chart by TradingView
    Basic chart:

    Profile

    Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. It is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. The company was incorporated in 2017 and is headquartered in La Jolla, California.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Immunology Immune System Tumor Platform Technology Chimeric Antigen Receptor T Cell T Cell Clusters Of Differentiation

    Is JANX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 19 Janux Therapeutics: Believable Theory, Strong Early Data, Needs Confirmation
    Nov 16 Bitdeer Technologies, PBF Energy, and More Stocks See Action From Activist Investors
    Nov 8 Janux Therapeutics Third Quarter 2024 Earnings: Misses Expectations
    Nov 7 Janux Therapeutics GAAP EPS of -$0.51 misses by $0.13, revenue of $0.44M misses by $1.23M
    Nov 6 Janux Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights
    Nov 1 Bath & Body Works, Paramount Global, and More Stocks See Action From Activist Investors
    Oct 16 Janux Therapeutics (NASDAQ:JANX) Is In A Strong Position To Grow Its Business
    Oct 7 Janux Therapeutics, Inc. (JANX): A Hot Stock to Buy Now
    Sep 26 Is Janux Therapeutics Inc. (JANX) the Best Performing Small-Cap Stock in 2024?
    Sep 20 Lennar, Bitdeer, and More Stocks See Action From Investor Activists
    See more JANX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 65.6
    52 Week Low 7.79
    Average Volume 662,980
    200-Day Moving Average 43.51
    50-Day Moving Average 50.06
    20-Day Moving Average 52.91
    10-Day Moving Average 51.26
    Average True Range 2.70
    RSI (14) 40.83
    ADX 31.96
    +DI 16.05
    -DI 20.09
    Chandelier Exit (Long, 3 ATRs) 49.96
    Chandelier Exit (Short, 3 ATRs) 55.14
    Upper Bollinger Bands 57.68
    Lower Bollinger Band 48.15
    Percent B (%b) 0.09
    BandWidth 18.01
    MACD Line -0.25
    MACD Signal Line 0.67
    MACD Histogram -0.9141
    Fundamentals Value
    Market Cap 2.26 Billion
    Num Shares 46.2 Million
    EPS -1.47
    Price-to-Earnings (P/E) Ratio -33.31
    Price-to-Sales 51.42
    Price-to-Book 1.22
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 51.56
    Resistance 3 (R3) 51.39 50.37 51.12
    Resistance 2 (R2) 50.37 49.71 50.45 50.98
    Resistance 1 (R1) 49.66 49.30 50.02 49.83 50.83
    Pivot Point 48.64 48.64 48.81 48.72 48.64
    Support 1 (S1) 47.93 47.98 48.29 48.10 47.09
    Support 2 (S2) 46.91 47.57 46.99 46.94
    Support 3 (S3) 46.20 46.91 46.80
    Support 4 (S4) 46.37